Shanghai Kehua Bio-Engineering Co Ltd (002022) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Kehua Bio-Engineering Co Ltd (002022) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥28.25 Million ≈ $4.13 Million USD) by net assets (CN¥3.70 Billion ≈ $541.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 002022 stock market capitalisation for the company's overall valuation and market capitalisation.
Shanghai Kehua Bio-Engineering Co Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Shanghai Kehua Bio-Engineering Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shanghai Kehua Bio-Engineering Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Kehua Bio-Engineering Co Ltd ranked by their cash flow conversion efficiency. Explore 002022 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
0.039x |
|
St Barbara Limited
F:BM1
|
0.008x |
|
Jay Mart Public Company Limited
BK:JMART
|
0.025x |
|
Doright Co.Ltd.
SHE:300950
|
-0.007x |
|
Kunwu Jiuding Investment Holdings Co Ltd
SHG:600053
|
-0.037x |
|
Regulus Resources Inc
V:REG
|
-0.007x |
|
Invesco Mortgage Capital Inc
NYSE:IVR
|
0.047x |
|
Thaitheparos Public Company Limited
BK:SAUCE
|
0.029x |
Annual Cash Flow Conversion Efficiency for Shanghai Kehua Bio-Engineering Co Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Kehua Bio-Engineering Co Ltd from 2002 to 2025. View Shanghai Kehua Bio-Engineering Co Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.11 Billion ≈ $455.03 Million |
CN¥22.44 Million ≈ $3.28 Million |
0.007x | +157.34% |
| 2024-12-31 | CN¥3.98 Billion ≈ $582.75 Million |
CN¥-50.12 Million ≈ $-7.33 Million |
-0.013x | +86.79% |
| 2023-12-31 | CN¥4.98 Billion ≈ $729.35 Million |
CN¥-474.89 Million ≈ $-69.49 Million |
-0.095x | -125.89% |
| 2022-12-31 | CN¥5.85 Billion ≈ $856.33 Million |
CN¥2.15 Billion ≈ $315.14 Million |
0.368x | +74.98% |
| 2021-12-31 | CN¥5.13 Billion ≈ $750.87 Million |
CN¥1.08 Billion ≈ $157.92 Million |
0.210x | -40.02% |
| 2020-12-31 | CN¥3.90 Billion ≈ $570.55 Million |
CN¥1.37 Billion ≈ $200.06 Million |
0.351x | +279.08% |
| 2019-12-31 | CN¥2.69 Billion ≈ $393.70 Million |
CN¥248.87 Million ≈ $36.42 Million |
0.093x | +77.28% |
| 2018-12-31 | CN¥2.43 Billion ≈ $355.59 Million |
CN¥126.79 Million ≈ $18.55 Million |
0.052x | -17.01% |
| 2017-12-31 | CN¥2.08 Billion ≈ $304.24 Million |
CN¥130.71 Million ≈ $19.13 Million |
0.063x | -57.51% |
| 2016-12-31 | CN¥1.90 Billion ≈ $278.14 Million |
CN¥281.25 Million ≈ $41.16 Million |
0.148x | +13.84% |
| 2015-12-31 | CN¥1.73 Billion ≈ $252.51 Million |
CN¥224.30 Million ≈ $32.82 Million |
0.130x | -34.00% |
| 2014-12-31 | CN¥1.27 Billion ≈ $185.50 Million |
CN¥249.64 Million ≈ $36.53 Million |
0.197x | -4.92% |
| 2013-12-31 | CN¥1.21 Billion ≈ $176.79 Million |
CN¥250.22 Million ≈ $36.62 Million |
0.207x | +5.27% |
| 2012-12-31 | CN¥1.09 Billion ≈ $158.98 Million |
CN¥213.74 Million ≈ $31.28 Million |
0.197x | -8.18% |
| 2011-12-31 | CN¥1.03 Billion ≈ $150.12 Million |
CN¥219.80 Million ≈ $32.16 Million |
0.214x | -17.48% |
| 2010-12-31 | CN¥931.34 Million ≈ $136.28 Million |
CN¥241.83 Million ≈ $35.39 Million |
0.260x | -5.36% |
| 2009-12-31 | CN¥792.82 Million ≈ $116.01 Million |
CN¥217.51 Million ≈ $31.83 Million |
0.274x | +28.29% |
| 2008-12-31 | CN¥643.75 Million ≈ $94.20 Million |
CN¥137.66 Million ≈ $20.14 Million |
0.214x | -7.88% |
| 2007-12-31 | CN¥486.48 Million ≈ $71.19 Million |
CN¥112.93 Million ≈ $16.53 Million |
0.232x | +5.95% |
| 2006-12-31 | CN¥398.02 Million ≈ $58.24 Million |
CN¥87.21 Million ≈ $12.76 Million |
0.219x | +12.77% |
| 2005-12-31 | CN¥380.71 Million ≈ $55.71 Million |
CN¥73.97 Million ≈ $10.82 Million |
0.194x | +52.22% |
| 2004-12-31 | CN¥381.82 Million ≈ $55.87 Million |
CN¥48.74 Million ≈ $7.13 Million |
0.128x | -71.25% |
| 2003-12-31 | CN¥158.92 Million ≈ $23.26 Million |
CN¥70.57 Million ≈ $10.33 Million |
0.444x | +56.53% |
| 2002-12-31 | CN¥146.21 Million ≈ $21.39 Million |
CN¥41.48 Million ≈ $6.07 Million |
0.284x | -- |
About Shanghai Kehua Bio-Engineering Co Ltd
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more